Johnson & Johnson (J&J) MedTech highlighted its latest clinical and technological advancements recently at the European Society of Minimally Invasive Neurological Therapy (ESMINT) annual congress (3–5 September 2025, Marseille, France)—including via an encore podium presentation of the MEMBRANE study utilising the company’s Trufill n-BCA liquid embolic agent in middle meningeal artery (MMA) embolisation, and a scientific symposium focused on the Cereglide 92 device.
These activities coincide with the recent CE-mark approval of the Cereglide 92 aspiration system, which J&J describes as a next-generation super-bore catheter designed for the removal of emboli and thrombi from the neurovasculature.
“The ESMINT congress offers a unique opportunity to bring the European neurovascular community together around the science and procedural advances shaping the future of stroke and neurovascular care,” said Christian Cuzick, worldwide president of neurovascular at J&J MedTech. “From data on cSDH [chronic subdural haematoma] to the CE mark for our Cereglide 92 aspiration system, we’re continuing to expand our portfolio to support physicians in achieving safer, more effective outcomes across a wide range of neurovascular conditions.”
The Cereglide 92 aspiration system features a 0.092-inch inner diameter super-bore catheter with the Innerglide 9 delivery aid. It offers Brite-Line full-length fluoroscopic visibility, and TruCourse technology for enhanced trackability and tip control, according to J&J.
Cereglide 92 was introduced in the USA earlier this year, and J&J plans to initiate a phased rollout of the system across select European markets this autumn.
